Financial Architects (New Jersey)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Financial Architects (New Jersey)’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-160	Closed	-$15K	–	1189
2019 Q1	$15K	Hold	160	–	–	﹤0.01%	976
2018 Q4	$12K	Hold	160	–	–	﹤0.01%	947
2018 Q3	$14K	Buy	160 +50	+45%	+$5.03K	﹤0.01%	1007
2018 Q2	$11K	Sell	110 -30	-21%	-$2.98K	﹤0.01%	955
2018 Q1	$17K	Hold	140	–	–	﹤0.01%	918
2017 Q4	$18K	Hold	140	–	–	﹤0.01%	981
2017 Q3	$16K	Hold	140	–	–	﹤0.01%	1010
2017 Q2	$11K	Buy	140 +60	+75%	+$3.83K	﹤0.01%	1103
2017 Q1	$4K	Buy	+80	New	+$3.7K	﹤0.01%	1314

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Financial Architects (New Jersey)'s ALNY Position: Q2 2019 in Review

Financial Architects (New Jersey) sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2019, closing a stake of 160 shares — an estimated $15K sold.

Financial Architects (New Jersey) first reported a position in ALNY in Q1 2017 and held it in 9 quarters. The position peaked at $18K in Q4 2017. 290 funds tracked by Wall St. Rank hold ALNY as of Q2 2019.

Financial Architects (New Jersey) reported no remaining Alnylam Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Financial Architects (New Jersey) sold 160 Alnylam Pharmaceuticals shares in Q2 2019, an estimated $15K.
Financial Architects (New Jersey) first reported a position in Alnylam Pharmaceuticals in Q1 2017 and held it in 9 quarters.
Financial Architects (New Jersey)'s Alnylam Pharmaceuticals position peaked at $18K in Q4 2017.
290 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2019, filed 14 Aug 2019.